Fig. 2.

Mean inhibition rates per time sampling¹ and: (A) SARS-CoV2 infection:no past SARS-CoV-2 infection andpast SARS-CoV-2 infection;(B) gender:male andfemale;(C) age: < 40 years old,40-59 years old and > 60 years old;(D) comorbidities:no,yes;(E) use of immunosuppressive drugs:no,yes;(F) tobacco use:no,yes;(G) mild adverse events post vaccination:no,yes;(H) BMI: < 20,20.1–25,25.1–30 and > 30;(I) regular physical exercise:no,yes.

Sampling 1: samples collected approximately 3 months after the second vaccine dose (mean: 95.3 days, range: 52–135 days). Sampling 2: samples collected approximately 6 months after the second vaccine dose (mean: 184.6 days, range: 136–225 days).Sampling 3: samples collected approximately 9 months after the second vaccine dose (mean: 262.9 days, range: 226–322 days). Error Bars 95% CI SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; BMI: body mass index; CI: confidence interval